| 产品描述: | Finerenone (BAY 94-8862) 是第三代选择性、具有口服活性的、非甾体类盐皮质激素受体 (MR) 拮抗剂 (IC50=18 nM)。与糖皮质激素受体 (GR)、雄激素受体 (AR) 和孕酮受体 (AR) 相比,Finerenone 表现出良好的选择性 (>500-fold)。Finerenone 在心肾疾病研究中具有潜在的应用前景,如 2 型糖尿病和慢性肾脏疾病。 |
| 靶点: |
GlucocorticoidReceptor |
| 体内研究: |
Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Frömter (MWF) rat. |
| 参考文献: |
1. Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403.
2. González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.642 ml |
13.212 ml |
26.425 ml |
| 5 mM |
0.528 ml |
2.642 ml |
5.285 ml |
| 10 mM |
0.264 ml |
1.321 ml |
2.642 ml |
| 50 mM |
0.053 ml |
0.264 ml |
0.528 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |